Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 83.96B 72.02B 67.25B 61.7B 116B 8,025B 118B 794B 311B 4,025B 315B 308B 13,308B P/E 2026 *
19.5x
P/E 2027 * 16.7x
Enterprise Value 77.09B 66.13B 61.75B 56.66B 107B 7,369B 108B 729B 285B 3,696B 289B 283B 12,219B EV / Sales 2026 *
4.56x
EV / Sales 2027 * 3.99x
Free-Float
71.07%
Yield 2026 *
0.46%
Yield 2027 * 0.53%
1 day+3.78%
1 week+5.50%
Current month+10.26%
1 month+24.26%
3 months+33.53%
6 months+6.15%
Current year+8.94%
1 week 792.57
Extreme 792.57
844.92
1 month 637.8
Extreme 637.8
844.92
Current year 591.52
Extreme 591.52
844.92
1 year 541
Extreme 541
844.92
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 01/01/2001
Chief Executive Officer 73 08/01/1988
Director of Finance/CFO 55 05/02/2024
Director TitleAgeSince
Chairman 73 09/06/2023
Director/Board Member 85 01/06/1991
Director/Board Member 85 01/06/1991
Date Insider Type Main position Quantity % Market Cap.
10/8/26 Fiscal year

Director

1,200 0.0012%
10/8/26 Fiscal year

Director

2,400 0.0023%
2/7/26 Sell

Director

-200 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+3.78%+5.50%+46.51%+3.50% 80.91B
+2.80%+23.97%-23.89%-35.69% 53.62B
+0.85%-4.04%-2.31%+30.25% 50.13B
+0.23%-3.71%+11.44%+170.56% 47.97B
+4.24%+8.67%+63.02%-15.16% 31.41B
+176.97%+187.90%+520.79%+71.60% 25.14B
+4.05%+6.11%+51.28%+100.61% 25.03B
+1.66%+2.83%-3.58%+212.40% 21.45B
+0.22%+5.48%+65.69%+127.79% 16.93B
+1.17%+0.30%+71.26%+192.31% 16.22B
Average +1.56%+2.72%+80.02%+85.82% 36.88B
Weighted average by Cap. +1.97%+2.89%+58.19%+58.97%

Financials

2026 *2027 *
Net sales 16.92B 14.52B 13.55B 12.44B 23.38B 1,617B 23.77B 160B 62.63B 811B 63.54B 62.15B 2,682B 18.42B 15.8B 14.75B 13.54B 25.45B 1,760B 25.87B 174B 68.16B 883B 69.16B 67.65B 2,919B
Net income 4.77B 4.09B 3.82B 3.51B 6.6B 456B 6.71B 45.12B 17.67B 229B 17.92B 17.53B 757B 5.45B 4.67B 4.36B 4B 7.53B 520B 7.65B 51.47B 20.15B 261B 20.45B 20B 863B
Net Debt -6.87B -5.89B -5.5B -5.05B -9.49B -656B -9.65B -64.92B -25.42B -329B -25.79B -25.23B -1,089B -10.55B -9.05B -8.45B -7.76B -14.58B -1,009B -14.82B -99.75B -39.06B -506B -39.63B -38.77B -1,673B
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,410
Date Price Change Volume
19/08/26 US$840.84 +3.78% 748,810
18/08/26 US$810.24 +0.53% 779,072
17/08/26 US$805.93 +0.30% 541,306
14/08/26 US$803.48 -0.31% 425,600
13/08/26 US$805.97 +1.00% 709,747
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
840.84USD
Average target price
840.43USD
Spread / Average Target
-0.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REGN Stock